March 28 (Reuters) - Incyte said on Saturday its experimental skin disease drug showed long-term reduction of symptoms in two late-stage trials. The company tested the drug, povorcitinib, in patients ...
Insmed INSM announced that it is discontinuing the development of Brinsupri (brensocatib) for hidradenitis suppurativa (HS) following disappointing mid-stage study results. The decision comes after ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results